Article
Medicine, General & Internal
Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K. S. Salama, Brendan Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno-Neumann
Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Murat Yilmaz, Beliz Oztok Tekten
Summary: This study aimed to determine the potential role of postictal serum LDH activities in differentiating epileptic seizures from non-epileptic seizures. The results showed significantly higher LDH activities in patients with epileptic seizures compared to those with non-epileptic seizures, suggesting the potential use of LDH activities as a diagnostic tool in distinguishing between seizure types.
Article
Biotechnology & Applied Microbiology
Andrea Perez-Iturralde, Beatriz Carte, Rafael Aldabe
Summary: The study found that mTOR inhibitors have complex effects on AAV hepatic transduction efficiency, with rapamycin enhancing AAV transduction while RapaLink-1 and MLN0128 do not. This indicates that mTOR inhibition is not a straightforward strategy for improving AAV transduction, and more research is needed to elucidate the mechanisms involved in their effects.
HUMAN GENE THERAPY
(2021)
Article
Oncology
Ryunosuke Nakagawa, Hiroaki Iwamoto, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Norihito Akatani, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Yoshifumi Kadono, Atsushi Takamatsu, Kotaro Yoshida, Atsushi Mizokami
Summary: In recent years, treatment strategies for metastatic hormone-naive prostate cancer have changed significantly with the development of various agents. In this study, we aimed to identify prognostic factors for the appropriate choice of treatment in Japanese men with hormone-naive prostate cancer. We retrospectively analyzed the data of patients with bone or visceral metastases, and identified Gleason pattern 5 content, bone scan index >= 1.5, and lactate dehydrogenase levels >= 300 IU/L as prognostic factors. Based on these factors, a new prognostic model for overall survival was developed.
Review
Neurosciences
Henry Querfurth, Han-Kyu Lee
Summary: mTOR is involved in regulating energy metabolism, neuronal growth, insulin signaling, and autophagy, playing both beneficial and pathogenic roles in neurodegenerative diseases. Balanced actions of mTOR complexes may have implications for Alzheimer's disease, Parkinson's disease, Huntington's disease, Frontotemporal dementia, and Amyotrophic Lateral Sclerosis. Beyond rapamycin, rapalogs with improved tolerability and delivery modes hold promise in treating age-related conditions.
MOLECULAR NEURODEGENERATION
(2021)
Article
Biochemistry & Molecular Biology
Ning Liu, Ying Yang, Xuemeng Si, Hai Jia, Yunchang Zhang, Da Jiang, Zhaolai Dai, Zhenlong Wu
Summary: L-proline plays a crucial role in embryogenesis, placental development, and fetal growth. This study revealed that proline enhances cell viability, activates the mTORC1 signaling pathway, and modulates the intracellular redox environment. Proline regulates the expression of proline transporters and enzymes involved in redox balance, indicating its potential therapeutic benefits in various developmental processes.
Article
Medicine, Research & Experimental
Mohamed El-Tanani, Hamdi Nsairat, Alaa A. Aljabali, Angel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Gowhar A. Naikoo, Walhan Alshaer, Murtaza M. Tambuwala
Summary: The mammalian target of rapamycin (mTOR), a signalling system, is necessary for various cell proliferation activities. It recognizes PI3KAKT stress signals as a serine-threonine kinase. The abnormal regulation of mTOR pathway has been proven to be crucial in cancer growth and advancement. This review primarily discusses the normal functions of mTOR as well as its abnormal roles in cancer development.
Article
Chemistry, Analytical
Justyna Glowacka, Agnieszka Wisniewska, Robert Koncki, Kamil Strzelak
Summary: In this study, two modifications of the routine LDH activity assay based on the use of reducing properties of NADH were compared. A fully-mechanized MCFA-PEDD system was developed for accurate measurement of LDH activity in serum samples. The linear ranges obtained for Fe-ferrozine and NBT methods were 6.0-200.0 U L-1 and 10.0-250.0 U L-1 with estimated detection limits at 0.2 U L-1 and 4.5 U L-1, respectively. The Fe-ferrozine method showed higher selectivity for LDH activity in the presence of glucose, ascorbic acid, albumin, bilirubin, copper and calcium ions.
Article
Oncology
Jialing Wu, Kaiyun You, Changlong Chen, Huimin Zhong, Yanhui Jiang, Huaqian Mo, Juanjuan Song, Xingsheng Qiu, Yimin Liu
Summary: This study retrospectively analyzed data from 198 patients with hypopharyngeal cancer and found that elevated pretreatment LDH levels were associated with poorer disease-free survival and overall survival. LDH was confirmed to be an independent predictor for both DFS and OS in multivariate analysis. Additional factors such as N status and age were also significantly associated with clinical outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Manyun Mao, Yating Dian, Yuming Sun, Wangqing Chen, Wu Zhu, Guangtong Deng
Summary: This study analyzed the data of 351 hospitalized COVID-19 patients treated with Azvudine and found that high levels of LDH were associated with disease progression.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Clinical Neurology
Xiao-Yong Chen, Jin-Yuan Chen, Yue Chen, Jia-Fang Chen, Ni Lin, Chen-Yu Ding, De-Zhi Kang, Deng-Liang Wang, Wen-Hua Fang
Summary: This study demonstrated that preoperative serum LDH level is closely related to the prognosis of glioma patients, serving as a reliable predictive indicator when combined with WHO grade and other factors for survival analysis. Further multicenter studies are needed to confirm these findings.
CLINICAL NEUROLOGY AND NEUROSURGERY
(2021)
Article
Biochemistry & Molecular Biology
Alaa Abou Daher, Sahar Alkhansa, William S. Azar, Rim Rafeh, Hilda E. Ghadieh, Assaad A. Eid
Summary: Understanding the mechanisms behind diabetic nephropathy (DN) is crucial for developing effective treatments. The mTOR pathway has been identified as a key player in diabetes-induced kidney injury, through its involvement in insulin resistance, oxidative stress, and autophagy regulation.
ANTIOXIDANTS & REDOX SIGNALING
(2022)
Article
Chemistry, Multidisciplinary
Xiangling Ren, Xinyuan Huang, Qiong Wu, Longfei Tan, Changhui Fu, Yi Chen, Xianwei Meng
Summary: Metal organic frameworks were found to inhibit the activity of pyruvate kinase in tumor cells, with nanoscale ZIF-8 showing the ability to inhibit glycolysis. The inhibitory effect is attributed to the zinc ions in ZIF-8, which has an IC50 one percent of that of zinc ion. This novel enzyme inhibitor holds promise for cancer therapy.
CHINESE CHEMICAL LETTERS
(2021)
Article
Genetics & Heredity
Oh Kwang Kwon, In Hyuk Bang, So Young Choi, Ju Mi Jeon, Ann-Yae Na, Yan Gao, Sam Seok Cho, Sung Hwan Ki, Youngshik Choe, Jun Nyung Lee, Yun-Sok Ha, Eun Ju Bae, Tae Gyun Kwon, Byung-Hyun Park, Sangkyu Lee
Summary: This study reveals the reduction of SIRT5 protein expression and LDHA-K118su as a novel mechanism involved in PCa progression, which could serve as a new target to prevent CPRC progression for PCa treatment.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2023)
Article
Cell Biology
Mark S. Sharpley, Fangtao Chi, Johanna ten Hoeve, Utpal Banerjee
Summary: Mammalian preimplantation embryos exhibit a certain level of metabolic plasticity during development, with adjustments occurring as developmental stages progress. In early stages, metabolism is tightly controlled by nutrient requirements, but as development matures, metabolic activity increases with enhanced adaptability.
DEVELOPMENTAL CELL
(2021)
Article
Urology & Nephrology
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin
Summary: The voting results from the 2021 Advanced Prostate Cancer Consensus Conference provide guidance for clinicians and patients in the management of advanced prostate cancer where evidence is scarce. However, treatment decisions should be individualized based on patient characteristics and current clinical evidence.
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Article
Oncology
Douglas B. Johnson, Michael B. Atkins, Cassandra Hennessy, Trisha Wise-Draper, Hannah Heilman, Joy Awosika, Ziad Bakouny, Chris Labaki, Renee Maria Saliby, Clara Hwang, Sunny R. K. Singh, Nino Balanchivadze, Christopher R. Friese, Leslie A. Fecher, James J. Yoon, Brandon Hayes-Lattin, Mehmet A. Bilen, Cecilia A. Castellano, Gary H. Lyman, Lisa Tachiki, Sumit A. Shah, Michael J. Glover, Daniel B. Flora, Elizabeth Wulff-Burchfield, Anup Kasi, Saqib H. Abbasi, Dimitrios Farmakiotis, Kendra Viera, Elizabeth J. Klein, Lisa B. Weissman, Chinmay Jani, Matthew Puc, Catherine C. Fahey, Daniel Y. Reuben, Sanjay Mishra, Alicia Beeghly-Fadiel, Benjamin French, Jeremy L. Warner
Summary: This study examined the impact of melanoma therapies on COVID-19 severity and organ dysfunction. The results showed that melanoma therapies did not increase the severity of COVID-19 or worsen organ dysfunction. Additionally, patients with a history of melanoma had similar 90-day survival compared with other cancer survivors after COVID-19.
Article
Oncology
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Summary: PSMA-targeted radioligand therapy has significantly improved clinical outcomes in men with mCRPC. A liquid biopsy characterizing PSMA expression could be useful in guiding optimal therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Michael J. Morris, Glenn Heller, David W. Hillman, Olivia Bobek, Charles Ryan, Emmanuel S. Antonarakis, Alan H. Bryce, Olwen Hahn, Himisha Beltran, Andrew J. Armstrong, Lawrence Schwartz, Lionel D. Lewis, Jan H. Beumer, Brooke Langevin, Eric C. McGary, Paul T. Mehan, Amir Goldkorn, Bruce J. Roth, Han Xiao, Colleen Watt, Mary-Ellen Taplin, Susan Halabi, Eric J. Small
Summary: The purpose of this study was to determine whether the addition of abiraterone acetate and prednisone (AAP) to enzalutamide prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the first-line setting. The results showed that the addition of AAP did not provide a statistically significant benefit in OS compared to enzalutamide treatment alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly
Summary: This study validated a prognostic model of overall survival in men with metastatic, castration-resistant prostate cancer treated with docetaxel. The model accurately predicts the survival of patients and performs well across different racial, age, and treatment subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Mosunmoluwa Oyenuga, Susan Halabi, Abayomi Oyenuga, Sean McSweeney, Alicia K. K. Morgans, Charles J. J. Ryan, Anna Prizment
Summary: This study examined the association between the pretreatment Halabi score and quality of life (QOL) outcomes in metastatic castration-resistant prostate cancer patients. The results showed that a higher Halabi score was associated with worse QOL outcomes at baseline and during follow-up.
Article
Medicine, General & Internal
Hwanhee Hong, Anne Friedland, Mengyi Hu, Kevin J. Anstrom, Susan Halabi, John E. McKinnon, Ravi Amaravadi, Jorge Rojas-Serrano, Benjamin S. Abella, Angelica Margarita Portillo-Vazquez, Christopher W. Woods, Adrian F. Hernandez, David R. Boulware, Susanna Naggie, Radha Rajasingham
Summary: In a meta-analysis of 10 randomized controlled trials, the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs) were studied. The results showed that compared to placebo, HCQ did not significantly reduce the risk of PCR-confirmed or clinically suspected SARS-CoV-2 infection, but significantly increased the incidence of adverse events.
Editorial Material
Oncology
L. Castelo-Branco, R. Lee, M. Brandao, A. Cortellini, A. Freitas, M. Garassino, T. Geukens, P. Grivas, S. Halabi, J. Oliveira, D. J. Pinato, J. Ribeiro, S. Peters, G. Pentheroudakis, J. L. Warner, E. Romano
Article
Medicine, General & Internal
Jane A. O'Halloran, Emily R. Ko, Kevin J. Anstrom, Eyal Kedar, Matthew W. McCarthy, Reynold A. Panettieri Jr, Martin Maillo, Patricia Segura Nunez, Anne M. Lachiewicz, Cynthia Gonzalez, P. Brian Smith, Sabina Mendivil-Tuchia de Tai, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo Capo, Daniel Rodriguez Gonzalez, Thomas F. Patterson, Christopher Palma, Horacio Ariza, Maria Patelli Lima, John Blamoun, Esteban C. Nannini, Eduardo Sprinz, Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Jennifer P. Wang, Luis Parra-Rodriguez, Tatyana Der, Kate Willsey, Jun Wen, Adam Silverstein, Sean M. O'Brien, Hussein R. Al-Khalidi, Michael A. Maldonado, Richard Melsheimer, William G. Ferguson, Steven E. McNulty, Pearl Zakroysky, Susan Halabi, Daniel K. Benjamin Jr, Sandra Butler, Jane C. Atkinson, Stacey J. Adam, Soju Chang, Lisa LaVange, Michael Proschan, Samuel A. Bozzette, William G. Powderly
Summary: This study investigated the benefits of adding abatacept, cenicriviroc, or infliximab to standard care for COVID-19 pneumonia. The results showed that there was no significant difference in the time to recovery from COVID-19 pneumonia between the treatment groups and the placebo group.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Oncology
Susan F. Slovin, Karen Knudsen, Susan Halabi, Renee de Leeuw, Ayesha Shafi, Praneet Kang, Steven Wolf, Bin Luo, Anuradha Gopalan, Tracy Curley, Mark Fleming, Ana Molina, Celina Fernandez, Kevin Kelly
Summary: Upfront combination therapy in chemotherapy/ARSI-naive mCRPC patients showed improved radiographic progression-free survival and may benefit some men, but further research is needed to identify the specific population that would benefit from this treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Takayuki Sumiyoshi, Xiaofei Wang, Evan W. Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Shengyu Ku, Ladan Fazli, James Eastham, Mary-Ellen Taplin, Jeffrey Simko, Susan Halabi, Michael J. Morris, Martin E. Gleave, Alexander W. Wyatt, Himisha Beltran
Summary: This study analyzed the molecular features of post-treated tumors in high-risk localized prostate cancer patients who received neoadjuvant chemohormonal therapy, revealing that lower tumor fraction after chemohormonal therapy was associated with poor outcomes, while TP53 alterations and high cell cycle transcriptomic activity were linked to aggressive residual disease.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Meeting Abstract
Urology & Nephrology
Rahul Aggarwal, Scott Eggener, Glenn Heller, Habn Xiao, David Hillman, Joel Picus, Jennifer Wang, Mary Ellen Taplin, Tanya Dorff, Leonard Appleman, Doug Weckstein, Akash Patnaik, Alan Bryce, Dan Shevrin, Susan Halabi, James Mohler, Daniel Anderson, Arpit Rao, Scott Tagawa, Alan Tan, Charles Ryan, Michael Morris
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Oncology
S. Gupta, Q. Yang, S. Halabi, A. Tubbs, Y. Gore, D. J. George, D. M. Nanus, E. S. Antonarakis, D. Danila, R. Szmulewitz, R. J. Wenstrup, A. J. Armstrong
ANNALS OF ONCOLOGY
(2022)